(Q46107336)

English

Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch

scientific article published on 26 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Gilbert Lefèvre

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Monika Büche

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Greg Sedek

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Steve Maton

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Albert Enz

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Ulrike Lorch

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Cyriaque Sagan

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

Silke Appel-Dingemanse

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

publication date

26 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

49

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

430-443

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Rivastigmine exposure provided by a transdermal patch versus capsules.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

A new and rapid colorimetric determination of acetylcholinesterase activity

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Confidence interval criteria for assessment of dose proportionality.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Absorption of rivastigmine from different regions of the gastrointestinal tract in humans

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

https://api.crossref.org/works/10.1177%2F0091270008330161

21 January 2018

Identifiers

10.1177/0091270008330161

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19246725

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46107336&oldid=2144129154"